Leidos Biomedical Research Inc.

Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., operates the Frederick National Laboratory for Cancer Research as a Federally Funded Research and Development Center (FFRDC) for the National Cancer Institute, delivering biomedical research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing as a full-and-open prime contractor on cost-plus-fixed-fee delivery orders flowing from master indefinite delivery vehicles with NCI and the National Institute of Allergy and Infectious Diseases.

The vendor's federal footprint is entirely concentrated in the National Institutes of Health. NCI accounts for 190 awards carrying $179.35 billion in combined potential value—99% of the vendor's total contract value and 66% of all federal awards counted. NIAID places 75 awards worth $2.76 billion, and the National Center for Advancing Translational Sciences, National Institute of Neurological Disorders and Stroke, and FDA account for the remaining portfolio. Customer concentration is extreme: NCI and NIAID together represent 265 of 281 prime awards and $182.1 billion of $182.17 billion in potential value. The two master vehicles dominate work flow: NCI's single-award IDC 75N91019D00024 (worth $7.13 billion across 185 task orders) and NIAID's HHSN261201500003I (worth $1.28 billion across 85 task orders) channel the overwhelming majority of delivery orders.

Capability portfolio spans biomedical research support, specialized manufacturing, and campus facilities management. Representative work includes a $72.17 million NCI delivery order (awarded Sept. 29, 2026) for functional precision medicine and response assays across the Frederick campus; a $139.89 million NIAID operational order (Aug. 31, 2025) for research and facility operations across NIAID's Division of Clinical Research; and a $173.3 million NIAID order (June 1, 2023) for Phase 1 and Phase 2 clinical trials of next-generation COVID vaccines. The vendor manufactures monoclonal antibodies, gene therapy vectors, vaccine platforms, and chemistry, manufacturing, and controls support for therapeutic candidates. Recent specialized work includes AAV vector manufacturing for gene therapy ($13.97 million order, Sept. 12, 2022), mRNA vaccine capability establishment ($30.32 million order, Sept. 2, 2022), and clinical material technology development and pilot manufacturing for NIAID ($17.7 million order, Sept. 24, 2026). Place of performance is entirely Frederick, Maryland, with administrative oversight and FFRDC operation centered at the NCI Frederick campus and subordinate NIH institutes.

Activity has remained relatively stable over recent years: 31 awards in 2022, declining to 19 in 2023, then recovering to 21 (2024), 24 (2025), and 25 (2026). However, eighty awards with ultimate completion dates in the next twenty-four months carry combined potential value of $2.51 billion, presenting substantial recompete exposure. This recompete cliff is driven by the two master IDCs' task-order calendars, not by IDC recompetes themselves—the underlying NCI and NIAID master vehicles carry multi-year periods and are not currently facing recompete.

SCI-reported invoicing totaled $3.48 billion across FY2022–FY2025, with peak activity in FY2022 at $920.1 million across approximately 1,860 FTEs, declining to $844.6 million across 1,692 FTEs in FY2025. The vendor maintains a stable federal workforce of roughly 1,700–1,900 FTEs. Government-paid hourly rates span a wide range—from a 10th percentile of $72.39/hr (entry-level technical roles) through a median of $212.04/hr to a 90th percentile of $1,241.18/hr (senior specialized research and clinical leadership). Across SCI-reportable prime contracts, subcontractors perform approximately 34% of total contractor hours, naming 1,118 total subcontractors; this reflects the vendor's reliance on a broad network of specialized partners for diagnostics, laboratory automation, bioprocess systems, and academic collaborations. Named teaming partners include Abbott Molecular Inc., Tecan U.S. Inc., Bio-Rad Laboratories, Brooks Instrument LLC, and academic institutions such as the University of Pittsburgh, Stanford University, and Children's Hospital of Philadelphia.

Federal grant sub-award work is minimal. The vendor serves as a sub-recipient on three awards under Stanford University-led NIH grants focused on immunologic and virologic research and paraneoplastic syndrome investigation (awarded Sept. 30, 2026; Sept. 24, 2025; Dec. 19, 2023), performing high-resolution HLA and KIR genotyping, library preparation, and data analysis in support of neurological disease research.

Leidos Biomedical Research competes exclusively in full-and-open procurement; no set-aside activity is present in the source. As an FFRDC, the vendor is structurally barred from competing under SBA set-asides. The subsidiary operates under parent Leidos Holdings Inc.'s financial and operational umbrella, which supplies organizational resources and stability for multi-year, cost-reimbursable federal research infrastructure operations. The company has no recorded federal contract IDV seats, GWACs, or GSA schedules—all work flows through the NCI and NIAID master indefinite delivery vehicles.